Fig. 5

Lung-trapped MSCs secrete miR-181a-5p-enriched MSC-EVs into the myocardium through blood. A. Experimental scheme of MSC tracking in vivo. B. Representative stereomicroscopic images of lung tissue in mice administered with MSCs intravenously. Scale bar, 2 mm. C. Representative immunofluorescence images of eGFP (green) and PECAM-1 antibody (red) binding to lung tissue in mice intravenously administered with MSCs on 24 h. Scale bars, 50 μm. D. Quantitative proportion of eGFP⁺ EVs in serum EVs from mice injected with MSCs-WT or DF-MSCs (6 h, 12 h and, 24 h). E. Gluc activity of serum EVs from mice injected with MSCs-WT and Gluc-MSCs (6 h and 12 h) (n = 3) ^**P < 0.01, ^****P < 0.0001 vs PBS, ^##P < 0.01 vs 6 h. F. MiR-181a-5p levels of serum EV in mice administrated with PBS (control), Dox/PBS, Dox/Single dose, or Dox/Consecutive doses on days 7 and 14 (n = 5). ^*P < 0.05, ^**P < 0.01 vs PBS (Control), ^#P < 0.05, ^##P < 0.01, ^####P < 0.0001 vs Dox/PBS, ^&P < 0.05, ^&&P < 0.01 vs Dox/Single dose. G. MiR-181a-5p levels of ventricular tissue in mice administrated with PBS (Control), Dox/PBS, Dox/Single dose, or Dox/Consecutive doses on days 7 and 14 (n = 5). ^****P < 0.0001 vs PBS (Control), ^#P < 0.05 vs Dox/PBS, ^&&P < 0.01, ^&&&&P < 0.0001 vs Dox/Single dose. Data were analyzed by one-way ANOVA followed by Bonferroni post hoc test, unless specifically indicated